Share Email Print

Proceedings Paper

Evidence for benefits of intervention with LLLT in children's asthma
Author(s): C. Ailioaie; Laura Ailioaie
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Asthma is a clinical syndrome characterized by increased responsiveness of the tracheo-bronchial tree to a variety of stimuli. Because of ongoing inflammation even in mild asthmas, we applied as a new modality of treatment, LLLT and a leukotriene antagonist, in order to maximize lung functions and minimize symptomatology in children's asthma. A group of 21 children with mild persistent, moderate or severe asthma were followed for 12 months. The patients were randomly divided into 2 groups. Group 1 (11 patients) received laser therapy combined with Singulair. LLLT was performed with two GaAlAs diode lasers (670 and 830 nm, max output power 50 mW, respectively 300 mW), in cw or pulsed mode using extrameridian acupuncture points and scanning technique, 3 times a week, during 6 weeks. The treatment was repeated after one month-break, for 2 times. Group 2 (10 patients) was administered placebo laser and Singulair, following the same protocol of treatment. The clinical improvement and the immunological characteristics were significantly better in group 1, than in placebo laser group. LLLT and Singulair improve the long-term prognosis and at least partially reverse the natural history of the disease. We strongly recommend it as the most appropriate therapy for asthmatic children.

Paper Details

Date Published: 29 June 2001
PDF: 6 pages
Proc. SPIE 4430, ROMOPTO 2000: Sixth Conference on Optics, (29 June 2001); doi: 10.1117/12.432905
Show Author Affiliations
C. Ailioaie, Univ. of Medicine and Pharmacy (Romania)
Laura Ailioaie, Univ. of Medicine and Pharmacy (Romania)

Published in SPIE Proceedings Vol. 4430:
ROMOPTO 2000: Sixth Conference on Optics
Valentin I. Vlad, Editor(s)

© SPIE. Terms of Use
Back to Top